Comprehensive pan-cancer analysis of LAMA3: implications for prognosis and immunotherapy.

IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
American journal of translational research Pub Date : 2025-02-15 eCollection Date: 2025-01-01 DOI:10.62347/QYJW2277
Hui Huang, Wei Dong, Xuan Qin, Ali Usama, Anees Cheema, Chunlei Deng, Sara Sarfaraz, Qingyun Pan, Majid Alhomrani, Abdulhakeem S Alamri, Naif ALSuhaymi, Saleh A Alghamdi, Ahmad A Alghamdi, Su Zheng
{"title":"Comprehensive pan-cancer analysis of LAMA3: implications for prognosis and immunotherapy.","authors":"Hui Huang, Wei Dong, Xuan Qin, Ali Usama, Anees Cheema, Chunlei Deng, Sara Sarfaraz, Qingyun Pan, Majid Alhomrani, Abdulhakeem S Alamri, Naif ALSuhaymi, Saleh A Alghamdi, Ahmad A Alghamdi, Su Zheng","doi":"10.62347/QYJW2277","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Laminin subunit alpha 3 (LAMA3) has been implicated in various cellular processes relevant to cancer progression, including cell proliferation, migration, and adhesion. In this study, we explored the expression, prognostic significance, and functional role of LAMA3 across multiple cancer types.</p><p><strong>Methodology: </strong>The in silico analyses involve using various bioinformatics tools and databases, such as The Cancer Genome Atlas (TCGA), TIMER2.0, GEPIA2, UALCAN, Kaplan-Meier (KM) plotter, GENT2, Human Protein Atlas (HPA), OncoDB, Gene Set Cancer Analysis (GSCA), and TISIDB. The in vitro analyses include cell culture, gene knockdown, and assays for cell proliferation, colony formation, and wound healing.</p><p><strong>Results: </strong>Pan-cancer analysis revealed significant variations in LAMA3 expression, with upregulation observed in cancers such as pancreatic adenocarcinoma (PAAD) and stomach adenocarcinoma (STAD), and downregulation in breast cancer (BRCA) and colon adenocarcinoma (COAD). Prognostic analyses indicated high LAMA3 expression correlated with poor overall survival (OS) in PAAD and STAD, whereas low expression was associated with adverse outcomes in BRCA. Validation analysis confirmed differential expression and localized LAMA3 primarily to the endoplasmic reticulum. Analysis of clinical features in BRCA, PAAD, and STAD showed consistent expression trends across different stages, races, and age groups. Additionally, mutational and copy number variations (CNVs) analyses revealed prevalent heterozygous amplifications and deletions in LAMA3 across BRCA, PAAD, and STAD. Promoter methylation was inversely correlated with LAMA3 expression in BRCA, PAAD, and STAD, although survival outcomes were unaffected. Protein-protein interaction (PPI) and gene enrichment analyses indicated LAMA3's involvement in ECM-receptor interactions and PI3K-Akt signaling, pathways critical in cancer. Finally, functional assays following LAMA3 knockdown in HT-29 cells demonstrated reduced cell proliferation, colony formation, and wound healing, implicating LAMA3 in tumor growth and metastasis.</p><p><strong>Conclusion: </strong>Overall, these findings suggest that LAMA3 plays a multifaceted role in tumorigenesis and holds potential as a prognostic biomarker and therapeutic target in multiple cancers.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 2","pages":"1200-1222"},"PeriodicalIF":1.7000,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909552/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of translational research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/QYJW2277","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Laminin subunit alpha 3 (LAMA3) has been implicated in various cellular processes relevant to cancer progression, including cell proliferation, migration, and adhesion. In this study, we explored the expression, prognostic significance, and functional role of LAMA3 across multiple cancer types.

Methodology: The in silico analyses involve using various bioinformatics tools and databases, such as The Cancer Genome Atlas (TCGA), TIMER2.0, GEPIA2, UALCAN, Kaplan-Meier (KM) plotter, GENT2, Human Protein Atlas (HPA), OncoDB, Gene Set Cancer Analysis (GSCA), and TISIDB. The in vitro analyses include cell culture, gene knockdown, and assays for cell proliferation, colony formation, and wound healing.

Results: Pan-cancer analysis revealed significant variations in LAMA3 expression, with upregulation observed in cancers such as pancreatic adenocarcinoma (PAAD) and stomach adenocarcinoma (STAD), and downregulation in breast cancer (BRCA) and colon adenocarcinoma (COAD). Prognostic analyses indicated high LAMA3 expression correlated with poor overall survival (OS) in PAAD and STAD, whereas low expression was associated with adverse outcomes in BRCA. Validation analysis confirmed differential expression and localized LAMA3 primarily to the endoplasmic reticulum. Analysis of clinical features in BRCA, PAAD, and STAD showed consistent expression trends across different stages, races, and age groups. Additionally, mutational and copy number variations (CNVs) analyses revealed prevalent heterozygous amplifications and deletions in LAMA3 across BRCA, PAAD, and STAD. Promoter methylation was inversely correlated with LAMA3 expression in BRCA, PAAD, and STAD, although survival outcomes were unaffected. Protein-protein interaction (PPI) and gene enrichment analyses indicated LAMA3's involvement in ECM-receptor interactions and PI3K-Akt signaling, pathways critical in cancer. Finally, functional assays following LAMA3 knockdown in HT-29 cells demonstrated reduced cell proliferation, colony formation, and wound healing, implicating LAMA3 in tumor growth and metastasis.

Conclusion: Overall, these findings suggest that LAMA3 plays a multifaceted role in tumorigenesis and holds potential as a prognostic biomarker and therapeutic target in multiple cancers.

LAMA3 泛癌症综合分析:对预后和免疫疗法的影响
目的:层粘连蛋白亚单位- α 3 (LAMA3)参与了与癌症进展相关的各种细胞过程,包括细胞增殖、迁移和粘附。在这项研究中,我们探讨了LAMA3在多种癌症类型中的表达、预后意义和功能作用。方法:计算机分析涉及使用各种生物信息学工具和数据库,如癌症基因组图谱(TCGA)、TIMER2.0、GEPIA2、UALCAN、Kaplan-Meier (KM)绘图仪、gen2、人类蛋白质图谱(HPA)、OncoDB、基因集癌症分析(GSCA)和TISIDB。体外分析包括细胞培养、基因敲除、细胞增殖、菌落形成和伤口愈合试验。结果:泛癌分析显示LAMA3表达存在显著差异,在胰腺腺癌(PAAD)和胃腺癌(STAD)等癌症中表达上调,在乳腺癌(BRCA)和结肠腺癌(COAD)中表达下调。预后分析显示,在PAAD和STAD中,LAMA3高表达与较差的总生存期(OS)相关,而在BRCA中,低表达与不良预后相关。验证分析证实了LAMA3的差异表达和主要定位于内质网。BRCA、PAAD和STAD的临床特征分析显示,不同阶段、种族和年龄组的表达趋势一致。此外,突变和拷贝数变异(CNVs)分析显示,LAMA3在BRCA、PAAD和STAD中普遍存在杂合扩增和缺失。在BRCA、PAAD和STAD中,启动子甲基化与LAMA3表达呈负相关,尽管生存结果不受影响。蛋白-蛋白相互作用(PPI)和基因富集分析表明LAMA3参与ecm受体相互作用和PI3K-Akt信号通路,这是癌症的关键途径。最后,在HT-29细胞中,LAMA3敲除后的功能分析显示,细胞增殖、集落形成和伤口愈合减少,这表明LAMA3与肿瘤生长和转移有关。结论:总的来说,这些发现表明LAMA3在肿瘤发生中起着多方面的作用,并具有作为多种癌症的预后生物标志物和治疗靶点的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
American journal of translational research
American journal of translational research ONCOLOGY-MEDICINE, RESEARCH & EXPERIMENTAL
自引率
0.00%
发文量
552
期刊介绍: Information not localized
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信